<style face="normal" font="default" size="100%">493 Identification of different classes of antagonist monoclonal antibodies targeting the myeloid checkpoint CLEC-1 and their associated anti-tumoral <em>in vivo</em> efficacies in humanized preclinical models</style>

Drupal-HighWire